Endocrine hypertension: Diagnosis and management of a complex clinical entity

Current Vascular Pharmacology

Volumn 8, Issue 5, 2010, Pages 646-660

  Anagnostis, Panagiotis ^a   Karagiannis, Asterios ^b   Tziomalos, Konstantinos ^b   Athyros, Vasilios G ^b   Kita, Marina ^a   Mikhailidis, Dimitri P ^c  

^a Aristotle University of Thessaloniki   (Greece)

^b ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cushing's syndrome; Endocrine hypertension; Pheochromocytoma; Primary aldosteronism

Indexed keywords

AMILORIDE; AMINOGLUTETHIMIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BROMOCRIPTINE; CALCIUM CHANNEL BLOCKING AGENT; CANRENOATE POTASSIUM; CATECHOLAMINE; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; GLUCOCORTICOID; GROWTH HORMONE; KETOCONAZOLE; LEVOTHYROXINE; METIROSINE; METYRAPONE; MINERALOCORTICOID; MITOTANE; OCTREOTIDE; PEGVISOMANT; PRAZOSIN; SOMATOSTATIN; SPIRONOLACTONE; TERAZOSIN; THIAZIDE DIURETIC AGENT; TRIAMTERENE;

ACROMEGALY; ADRENAL HYPERPLASIA; CLINICAL FEATURE; CUSHING SYNDROME; GORDON SYNDROME; GROWTH DISORDER; HYPERTENSION; LIDDLE SYNDROME; PARATHYROID GLAND; PHEOCHROMOCYTOMA; PRIMARY HYPERALDOSTERONISM; PRIMARY HYPERPARATHYROIDISM; REVIEW; THYROID DISEASE; THYROID GLAND; THYROIDECTOMY; ADULT; BLOOD; CHILD; CLASSIFICATION; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; ENDOCRINE DISEASE; FEMALE; HUMAN; MALE; PATHOPHYSIOLOGY;

ADULT; CHILD; DIAGNOSIS, DIFFERENTIAL; EARLY DIAGNOSIS; ENDOCRINE SYSTEM DISEASES; FEMALE; HUMANS; HYPERTENSION; MALE;

EID: 79956078708     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016110792006996     Document Type: Review

References (165)

1. Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension, prevalenceand blood pressure levels in 6 European countries, Canadaand the United States. JAMA 2003; 289: 2363-9.
2. Yusuf S, Hawken S, Ounpuu S, et al.; INTERHEART Study Investigators.Effect of potentially modifiable risk factors associatedwith myocardial infarction in 52 countries (the INTERHEARTstudy): case-control study. Lancet 2004; 364: 937-52.
3. Kearney PM, Whelton M, Reynolds K Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet2005; 365: 217-23.
4. Karagiannis A, Douma S, Voyiatzis K, et al. Percutaneous transluminalrenal angioplasty in patients with renovascular hypertension:long-term results. Hypertens Res 1995; 18: 27-31.
5. Karagiannis A, Tziomalos K, Anagnostis P, Gossios T, Athyros V. Atherosclerotic renal artery stenosis: medical therapy alone or incombination with revascularization? Angiology 2009; 60: 397-402.
6. Mancia G, De Backer G, Dominiczak A, et al. The task force for the management of arterial hypertension of the European Society ofHypertension, The task force for the management of arterial hypertension of the European Society of Cardiology. 2007 Guidelines forthe management of arterial hypertension: The Task Force for theManagement of Arterial Hypertension of the European Society ofHypertension (ESH) and of the European Society of Cardiology(ESC). Eur Heart J 2007; 28: 1462-536.
7. Rossi GP, Bernini G, Caliumi C, et al.; PAPY Study Investigators.A prospective study of the prevalence of primary aldosteronism in1,125 hypertensive patients. J Am Coll Cardiol 2006; 48: 2293-300.
8. Moser M, Setaro JF., Clinical practice. Resistant or difficult-tocontrolhypertension. N Engl J Med 2006; 355: 385-92.
9. Stowasser M. Primary aldosteronism: rare bird or common cause ofsecondary hypertension? Curr Hypertens Rep 2001; 3: 230-9.
10. Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Rutherford JC. High incidence of primary hyperaldosteronism in 199 patients referredwith hypertension. Clin Exp Pharmacol Physiol 1994; 21:315-8.
11. Giacchetti G, Turchi F, Boscaro M, Ronconi V. Management ofprimary aldosteronism: its complications and their outcomes aftertreatment. Curr Vasc Pharmacol 2009; 7: 244-9.
12. Lim PO, Rodgers P, Cardale K, Watson AD, MacDonald TM. Potentially high prevalence of primary aldosteronism in a primarycarepopulation. Lancet 1999; 353: 40.
13. Loh K-C, Koay ES, Khaw M-C, Emmanuel SC, Young WF Jr. Prevalence of primary aldosteronism among Asian hypertensivepatients in Singapore. J Clin Endocrinol Metab 2000; 85: 2854-9.
14. Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf) 2007; 66: 607-18.
15. Calhoun DA, Jones D, Textor S, et al.; American Heart AssociationProfessional Education Committee. Resistant hypertension: diagnosis,evaluation, and treatment: a scientific statement from theAmerican Heart Association Professional Education Committee ofthe Council for High Blood Pressure Research. Circulation 2008;117: 510-26.
16. Karagiannis A, Tziomalos K, Kakafika A, Harsoulis F, Zamboulis C. Paralysis as first manifestation of primary aldosteronism. NephrolDial Transplant 2004; 19: 2418-9.
17. Funder JW, Carey RM, Fardella C, et al.; Endocrine Society. Casedetection, diagnosis, and treatment of patients with primary aldosteronism:an endocrine society clinical practice guideline. J ClinEndocrinol Metab 2008; 93: 3266-81.
18. Conn JW. Presidential address. I. Painting background. II. Primaryaldosteronism, a new clinical syndrome. J Lab Clin Med 1955; 45:3-17.
19. Lifton RP, Dluhy RG, Powers M, et al. A chimeric 11 betahydroxylase/aldosterone synthase gene causes glucocorticoidremediablealdosteronism and human hypertension. Nature 1992;355: 262-5.
20. Litchfield WR, Anderson BF, Weiss RJ, Lifton RP, Dluhy RG. Intracranial aneurysms and hemorrhagic stroke in glucocorticoidremediablealdosteronism. Hypertension 1998; 31: 445-50.
21. So A, Duffy DL, Gordon RD, et al. Familial hyperaldosteronismtype II is linked to the chromosome 7p22 region but also showspredicted heterogeneity. J Hypertens 2005; 23: 1477-84.
22. Geller DS, Zhang J, Wisgerhof MV, Shackleton C, Kashgarian M, Lifton RP. A novel form of human mendelian hypertension featuringnonglucocorticoid-remediable aldosteronism. J Clin EndocrinolMetab 2008; 93: 3117-23.
23. Karagiannis A, Mikhailidis DP, Athyros VG, Harsoulis F. Pheochromocytoma:an update on genetics and management. EndocrRelat Cancer 2007; 14: 935-56.
24. Bravo EL, Tagle R. Pheochromocytoma: state-of-the-art and futureprospects. Endocr Rev 2003; 24: 539-53.
25. Omura M, Saito J, Yamaguchi K, Kakuta Y, Nishikawa T. Prospective study on the prevalence of secondary hypertensionamong hypertensive patients visiting a general outpatient clinic inJapan. Hypertens Res 2004; 27: 193-202.
26. Anagnostis P, Karagiannis A, Tziomalos K, Kakafika AI, Athyros VG, Mikhailidis DP. Adrenal incidentaloma: a diagnostic challenge. Hormones (Athens) 2009; 8: 163-84.
27. Koch CA, Mauro D, Walther MM, et al. Pheochromocytoma invon Hippel-Lindau disease: distinct histopathologic phenotypecompared to pheochromocytoma in multiple endocrine neoplasiatype 2. Endocr Pathol 2002; 13: 17-27.
28. Amar L, Bertherat J, Baudin E, et al. Genetic testing in pheochromocytomaor functional paraganglioma. J Clin Oncol 2005; 23:8812-8.
29. Jiménez C, Cote G, Arnold A, Gagel RF. Review: should patientswith apparently sporadic pheochromocytomas or paragangliomasbe screened for hereditary syndromes? J Clin Endocrinol Metab2006; 91: 2851-8.
30. Erlic Z, Neumann HP. When should genetic testing be obtained ina patient with phaeochromocytoma or paraganglioma? Clin Endocrinol(Oxf) 2009; 70: 354-7.
31. Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet 2005; 366: 665-75.
32. Koch CA, Rodbard JS, Brouwers FM, Eisenhofer G, Pacak K. Hypotension in a woman with a metastatic dopamine-secreting carotidbody tumor. Endocr Pract 2003; 9: 310-4.
33. Walther MM, Reiter R, Keiser HR, et al. Clinical and genetic characterizationof pheochromocytoma in von Hippel-Lindau families:comparison with sporadic pheochromocytoma gives insight intonatural history of pheochromocytoma. J Urol 1999; 162: 659-64.
34. Otsuka F, Ogura T, Nakagawa M, et al. Normotensive bilateralpheochromocytoma with Lindau disease: case report. Endocr J1996; 43: 719-23.
35. Agarwal A, Gupta S, Mishra AK, Singh N, Mishra SK. Normotensivepheochromocytoma: institutional experience. World J Surg2005; 29: 1185-8.
36. Kopetschke R, Slisko M, Kilisli A, et al. Frequent incidental discoveryof phaeochromocytoma: data from a German cohort of 201phaeochromocytoma. Eur J Endocrinol 2009; 161: 355-61.
37. Bhansali A, Rajput R, Behra A, Rao KL, Khandelwal N, Radotra BD. Childhood sporadic pheochromocytoma: clinical profile andoutcome in 19 patients. J Pediatr Endocrinol Metab 2006; 19: 749-56.
38. Pons J, Lee EW, Li L, Kitlinska J. Neuropeptide Y: multiple receptorsand multiple roles in cardiovascular diseases. Curr Opin Investig Drugs 2004; 5: 957-62.
39. Magiakou MA, Smyrnaki P, Chrousos GP. Hypertension in Cushing'ssyndrome. Best Pract Res Clin Endocrinol Metab 2006; 20:467-82.
40. Lodish MB, Sinaii N, Patronas N, et al. Blood pressure in pediatricpatients with Cushing syndrome. J Clin Endocrinol Metab 2009;94: 2002-8.
41. Magiakou MA, Mastorakos G, Zachman K, Chrousos GP. Bloodpressure in children and adolescents with Cushing's syndrome beforeand after surgical care. J Clin Endocrinol Metab 1997; 82:1734-8.
42. Tauchmanovà L, Rossi R, Biondi B, et al. Patients with subclinicalCushing's syndrome due to adrenal adenoma have increased cardiovascularrisk. J Clin Endocrinol Metab 2002; 87: 4872-8.
43. Erbil Y, Ademoglu E, Ozbey N, et al. Evaluation of the cardiovascularrisk in patients with subclinical Cushing syndrome before andafter surgery. World J Surg 2006; 30: 1665-71.
44. Anagnostis P, Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. The pathogenetic role of cortisol in the metabolic syndrome:a hypothesis. J Clin Endocrinol Metab 2009; 94: 2692-701.
45. Fountoulakis S, Tsatsoulis A. Molecular genetic aspects and pathophysiologyof endocrine hypertension. Hormones (Athens) 2006; 5:90-106.
46. van Uum SH, Lenders JW, Hermus AR. Cortisol, 11betahydroxysteroiddehydrogenases, and hypertension. Semin VascMed 2004; 4: 121-8.
47. Prisant LM, Gujral JS, Mulloy AL. Hyperthyroidism: a secondarycause of isolated systolic hypertension. J Clin Hypertens (Greenwich)2006; 8: 596-9.
48. Klein I, Danzi S. Thyroid disease and the heart. Circulation 2007;116: 1725-35.
49. Biondi B, Cooper DS. The clinical significance of subclinical thyroiddysfunction. Endocr Rev 2008; 29: 76-131.
50. Volzke H, Ittermann T, Schmidt CO, et al. Subclinical hyperthyroidismand blood pressure in a population-based prospective cohortstudy. Eur J Endocrinol 2009; 161: 615-21.
51. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 2001; 344: 501-9.
52. Luboshitzky R, Aviv A, Herer P, Lavie L. Risk factors for cardiovasculardisease in women with subclinical hypothyroidism. Thyroid2002; 12: 421-5.
53. Kotsis V, Alevizaki M, Stabouli S, et al. Hypertension and hypothyroidism:results from an ambulatory blood pressure monitoringstudy. J Hypertens 2007; 25: 993-9.
54. Bilezikian JP, Khan AA, Potts JT Jr. Third International Workshopon the Management of Asymptomatic Primary Hyperparathyroidism.Guidelines for the management of asymptomatic primary hyperparathyroidism:summary statement from the third internationalworkshop. J Clin Endocrinol Metab 2009; 94: 335-9.
55. Mihai R, Wass JA, Sadler GP. Asymptomatic hyperparathyroidismneed for multicentre studies. Clin Endocrinol (Oxf) 2008; 68:155-64.
56. Dluhy RG. Uncommon forms of secondary hypertension in olderpatients. Am J Hypertens 1998; 11: 52S-56S.
57. Hulter HN, Melby JC, Peterson JC, Cooke CR. Chronic continuousPTH infusion results in hypertension in normal subjects. J Clin Hypertens 1986; 2: 360-70.
58. Morfis L, Smerdely P, Howes LG. Relationship between serumparathyroid hormone levels in the elderly and 24 h ambulatoryblood pressures. J Hypertens 1997; 15: 1271-6.
59. Brickman AS, Nyby MD, von Hungen K, Eggena P, Tuck ML. Calcitropic hormones, platelet calcium, and blood pressure in essentialhypertension. Hypertension 1990; 16: 515-22.
60. Ekmekci A, Abaci N, Ozbey NC, et al. Endothelial function andendothelial nitric oxide synthase intron 4a/b polymorphism in primaryhyperparathyroidism. J Endocrinol Invest. 2009; 32: 611-6.
61. Efstratiadis G, Tziomalos K, Mikhailidis DP, Athyros VG, Hatzitolios A. Atherogenesis in renal patients: a model of vascular disease? Curr Vasc Pharmacol 2008; 6: 93-107.
62. Rubin MR, Maurer MS, McMahon DJ, Bilezikian JP, Silverberg SJ. Arterial stiffness in mild primary hyperparathyroidism. J ClinEndocrinol Metab 2005; 90: 3326-30.
63. Walker MD, Fleischer J, Rundek T, et al. Carotid vascular abnormalitiesin primary hyperparathyroidism. J Clin Endocrinol Metab 2009; 94: 3849-56.
64. Lumachi F, Ermani M, Luisetto G, et al. Relationship betweenserum parathyroid hormone, serum calcium and arterial blood pressurein patients with primary hyperparathyroidism: results of a multivariateanalysis. Eur J Endocrinol 2002; 146: 643-7.
65. Melmed S. Acromegaly. N Engl J Med 2006; 355: 2558-73.
66. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complicationsof acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 2004; 25: 102-52.
67. Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP. Mortality in acromegaly: a metaanalysis. J ClinEndocrinol Metab 2008; 93: 61-7.
68. Bondanelli M, Ambrosio MR, degli Uberti EC. Pathogenesis andprevalence of hypertension in acromegaly. Pituitary 2001; 4: 239-49.
69. Rizzoni D, Porteri E, Giustina A, et al. Acromegalic patients showthe presence of hypertrophic remodeling of subcutaneous small resistancearteries. Hypertension 2004; 43: 561-5.
70. Minniti G, Moroni C, Jaffrain-Rea ML, et al. Prevalence of hypertensionin acromegalic patients: clinical measurement vs. 24-hourambulatory blood pressure monitoring. Clin Endocrinol (Oxf)1998; 48: 149-52.
71. Pietrobelli DJ, Akopian M, Olivieri AO, et al. Altered circadianblood pressure profile in patients with active acromegaly. Relationshipwith left ventricular mass and hormonal values. J Hum Hypertens2001; 15: 601-5.
72. Speiser PW, White PC. Congenital adrenal hyperplasia. N Engl JMed 2003; 349: 776-88.
73. Zachmann M, Tassinari D, Prader A. Clinical and biochemicalvariabilitiy of congenital adrenal hyperplasia due to 11betahydroxylasedeficiency. J Clin Endocrinol Metab 1983; 56: 222-9.
74. Wong SL, Shu SG, Tsai CR. Seventeen alpha-hydroxylase deficiency.J Formos Med Assoc 2006; 105: 177-81.
75. Wilson RC, Harbison MD, Krozowski ZS, et al. Several homozygousmutations in the gene for 11 beta-hydroxysteroid dehydrogenasetype 2 in patients with apparent mineralocorticoid excess. JClin Endocrinol Metab 1995; 80: 3145-50.
76. Wilson RC, Nimkarn S, New MI. Apparent mineralocorticoidexcess. Trends Endocrinol Metab 2001; 12: 104-11.
77. Botero-Velez M, Curtis JJ, Warnock DG. Brief report: Liddle'ssyndrome revisited--a disorder of sodium reabsorption in the distaltubule. N Engl J Med 1994; 330: 178-81.
78. Geller DS, Farhi A, Pinkerton N, et al. Activating mineralocorticoidreceptor mutation in hypertension exacerbated by pregnancy. Science 2000; 289: 119-23.
79. Gordon RD. Syndrome of hypertension and hyperkalemia withnormal glomerular filtration rate. Hypertension 1986; 8: 93-102.
80. Wilson FH, Disse-Nicodeme S, Choate KA, et al. Human hypertensioncaused by mutations in WNK kinases. Science 2001; 293:1107-12.
81. Kino T, Vottero A, Charmandari E, Chrousos GP. Familial/sporadic glucocorticoid resistatnce syndrome and hypertension. Ann N Y Acad Sci 2002; 970: 101-11.
82. Charmandari E, Kino T, Ichijo T, Chrousos GP. Generalized glucocorticoidresistance: clinical aspects, molecular mechanisms, andimplications of a rare genetic disorder. J Clin Endocrinol Metab2008; 93: 1563-72.
83. Montori VM, Young WF Jr. Use of plasma aldosterone concentration-to-plasma renin activity ratio as a screening test for primaryaldosteronism. A systematic review of the literature. EndocrinolMetab Clin North Am 2002; 31: 619-32.
84. Weinberger MH, Fineberg NS. The diagnosis of primary aldosteronismand separation of two major subtypes. Arch Intern Med 1993;153: 2125-9.
85. Stowasser M, Gordon RD. Primary aldosteronism: careful investigationis essential and rewarding. Mol Cell Endocrinol 2004; 217:33-9.
86. Mulatero P, Milan A, Fallo F, et al. Comparison of confirmatorytests for the diagnosis of primary aldosteronism. J Clin EndocrinolMetab 2006; 91: 2618-23.
87. Young WF, Stanson AW, Thompson GB, Grant CS, Farley DR, van Heerden JA. Role for adrenal venous sampling in primary aldosteronism. Surgery 2004; 136: 1227-35.
88. Gordon RD, Stowasser M, Rutherford JC. Primary aldosteronism:are we diagnosing and operating on too few patients? World J Surg 2001; 25: 941-7.
89. Murashima M, Trerotola SO, Fraker DL, Han D, Townsend RR, Cohen DL. Adrenal venous sampling for primary aldosteronismand clinical outcomes after unilateral adrenalectomy: a singlecenterexperience. J Clin Hypertens (Greenwich) 2009; 11: 316-23.
90. Young WF Jr, Stanson AW, Grant CS, Thompson GB, van Heerden JA. Primary aldosteronism: adrenal venous sampling. Surgery 1996; 120: 913-9.
91. Litchfield WR, New MI, Coolidge C, Lifton RP, Dluhy RG. Evaluation of the dexamethasone suppression test for the diagnosisof glucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab 1997; 82: 3570-3.
92. Sawka AM, Jaeschke R, Singh RJ, Young WF Jr. A comparison ofbiochemical tests for pheochromocytoma: measurement of fractionatedplasma metanephrines compared with the combination of24-hour urinary metanephrines and catecholamines. J Clin EndocrinolMetab 2003; 88: 553-8.
93. Boyle JG, Davidson DF, Perry CG, Connell JM. Comparison ofdiagnostic accuracy of urinary free metanephrines, vanillyl mandelicacid, and catecholamines and plasma catecholamines for diagnosisof pheochromocytoma. J Clin Endocrinol Metab 2007; 92:4602-8.
94. Miehle K, Kratzsch J, Lenders JW, Kluge R, Paschke R, Koch CA. Adrenal incidentaloma diagnosed as pheochromocytoma by plasmachromogranin A and plasma metanephrines. J Endocrinol Invest 2005; 28: 1040-2.
95. Algeciras-Schimnich A, Preissner CM, Young WF Jr, Singh RJ, Grebe SK. Plasma chromogranin A or urine fractionated metanephrinesfollow-up testing improves the diagnostic accuracy of plasmafractionated metanephrines for pheochromocytoma. J Clin EndocrinolMetab 2008; 93: 91-5.
96. Bhatia KS, Ismail MM, Sahdev A, et al. 123I-metaiodobenzylguanidine(MIBG) scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation. ClinEndocrinol (Oxf) 2008; 69: 181-8.
97. Ilias I, Pacak K. Current approaches and recommended algorithmfor the diagnostic localization of pheochromocytoma. J Clin EndocrinolMetab 2004; 89: 479-91.
98. Fujita A, Hyodoh H, Kawamura Y, Kanegae K, Furuse M, Kanazawa K. Use of fusion images of I-131 metaiodobenzylguanidine,SPECT, and magnetic resonance studies to identify a malignantpheochromocytoma. Clin Nucl Med 2000; 25: 440-2.
99. Cecchin D, Lumachi F, Marzola MC, et al. A metaiodobenzylguanidinescintigraphic scoring system increases accuracyin the diagnostic management of pheochromocytoma. EndocrRelat Cancer 2006; 13: 525-33.
100. Shapiro B, Gross MD, Shulkin B. Radioisotope diagnosis andtherapy of malignant pheochromocytoma. Trends Endocrinol Metab 2001; 12: 469-75.
101. Kaji P, Carrasquillo JA, Linehan WM, et al. The role of 6-[18F]fluorodopamine positron emission tomography in the localizationof adrenal pheochromocytoma associated with von Hippel-Lindau syndrome. Eur J Endocrinol 2007; 156: 483-7.
102. Lastoria S, Maurea S, Vergara E, et al. Comparison of labeledMIBG and somatostatin analogs in imaging neuroendocrine tumors.Q J Nucl Med 199; 39(4 Suppl 1): 145-9.
103. van der Harst E, de Herder WW, Bruining HA, et al. [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake inbegnign and malignant pheochromocytomas. J Clin EndocrinolMetab 2001; 86: 685-93.
104. Koopmans KP, Jager PL, Kema IP, Kerstens MN, Albers F, Dullaart RP. 111In-octreotide is superior to 123I-metaiodobenzylguanidinefor scintigraphic detection of head and neck paragangliomas. J Nucl Med 2008; 49: 1232-7.
105. Pacak K, Linehan WM, Eisenhofer G, Walther MM, Goldstein DS. Recent advances in genetics, diagnosis, localization, and treatmentof pheochromocytoma. Ann Intern Med 2001; 134: 315-29.
106. Findling JW, Raff H, Aron DC. The low-dose dexamethasonesuppression test: a reevaluation in patients with Cushing's syndrome. J Clin Endocrinol Metab 2004; 89: 1222-6.
107. Pecori GF, Ambrogio AG, De Martin M, Fatti LM, Scacchi M, Cavagnini F. Specificity of first-line tests for the diagnosis ofCushing's syndrome: assessment in a large series. J Clin EndocrinolMetab 2007; 92: 4123-9.
108. Yaneva M, Mosnier-Pudar H, Dugué MA, Grabar S, Fulla Y, Bertagna X. Midnight salivary cortisol for the initial diagnosis ofCushing's syndrome of various causes. J Clin Endocrinol Metab 2004; 89: 3345-51.
109. Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing'ssyndrome: an Endocrine Society Clinical Practice Guideline. JClin Endocrinol Metab 2008; 93: 1526-40.
110. Mazza A, Zamboni S, Armigliato M, et al. Endocrine arterial hypertension:diagnostic approach in clinical practice. Minerva Endocrinol 2008; 33: 127-46.
111. Tabarin A, Laurent F, Catargi B, et al. Comparative evaluation ofconventional and dynamic magnetic resonance imaging of the pituitarygland for the diagnosis of Cushing's disease. Clin Endocrinol(Oxf) 1998; 49: 293-300.
112. Spencer CA, Takeuchi M, Kazarosyan M. Current status and performancegoals for serum thyrotropin (TSH) assays. Clin Chem 1996; 42: 140-5.
113. Stockigt JR. Free thyroid hormone measurement. A critical appraisal.Endocrinol Metab Clin North Am 2001; 30: 265-89.
114. Pearce EN, Farwell AP, Braverman LE. Thyroiditis. N Engl J Med2003; 348: 2646-55.
115. Topliss DJ, Eastman CJ. Diagnosis and management of hyperthyroidismand hypothyroidism. Med J Aust 2004; 180: 186-93.
116. Bilezikian JP, Silverberg SJ. Clinical practice. Asymptomatic primaryhyperparathyroidism. N Engl J Med 2004; 350: 1746-51.
117. Eastell R, Arnold A, Brandi ML, et al. Diagnosis of asymptomaticprimary hyperparathyroidism: proceedings of the third internationalworkshop. J Clin Endocrinol Metab 2009; 94: 340-50.
118. Boudreaux BA, Magnuson JS, Asher SA, Desmond R, Peters GE.The role of ultrasonography in parathyroid surgery. Arch OtolaryngolHead Neck Surg 2007; 133: 1240-4.
119. Nguyen BD. Parathyroid imaging with Tc-99m sestamibi planarand SPECT scintigraphy. RadioGraphics 1999; 19: 601-14.
120. Lavely WC, Goetze S, Friedman KP, et al. Comparison ofSPECT/CT, SPECT, and planar imaging with single- and dualphase(99m)Tc-sestamibi parathyroid scintigraphy. J Nucl Med 2007; 48: 1084-9.
121. Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure ofacromegaly: a consensus statement. J Clin Endocrinol Metab 2000;85: 526-9.
122. Melmed S, Colao A, Barkan M, et al.; Acromegaly ConsensusGroup. Guidelines for acromegaly management: an update. J ClinEndocrinol Metab 2009; 94: 1509-17.
123. Dimaraki EV, Jaffe CA, DeMott-Friberg R, Chandler WF, Barkan AL. Acromegaly with apparently normal GH secretion: implicationsfor diagnosis and follow-up. J Clin Endocrinol Metab 2002;87: 3537-42.
124. Quinkler M, Oelkers W, Diederich S. In vivo measurement of renal11beta-hydroxysteroid dehydrogenase type 2 activity. J Clin EndocrinolMetab 2000; 85: 4921-3.
125. Liddle GW, Bledsoe T, Coppage WS Jr. A familial renal disordersimulating primary aldosteronism but with negligible aldosteronesecretion. Trans Assoc Am Physicians 1963; 76: 199-213.
126. Karagiannis A, Tziomalos K, Kakafika A, Athyros V, Harsoulis F, Mikhailidis D. Medical treatment as an alternative to adrenalectomyin patients with aldosterone-producing adenomas. Endocr RelatCancer 2008; 15: 693-700.
127. Ghose RP, Hall PM, Bravo EL. Medical management of aldosterone-producing adenomas. Ann Intern Med 1999; 131: 105-8.
128. Sica DA. Pharmacokinetics and pharmacodynamics of mineralocorticoidblocking agents and their effects on potassium homeostasis. Heart Fail Rev 2005; 10: 23-9.
129. Karagiannis A, Tziomalos K, Kakafika A, Florentin M, Athyros VG. Eplerenone relieves spironolactone-induced painful gynaecomastiain a patient with primary aldosteronism. Nephrol DialTransplant 2007; 22: 293.
130. Karagiannis A, Tziomalos K, Papageorgiou A, et al. Spironolactonevs. eplerenone for the treatment of idiopathic hyperaldosteronism. Expert Opin Pharmacother 2008; 9: 509-15.
131. Menard J, Gonzalez MF, Guyenne TT, Bissery A. Investigation ofaldosterone-synthase inhibition in rats. J Hypertens 2006; 24: 1147-55.
132. Raizada MK, Francis SC, Wang H, Gelband CH, Reaves PY, Katovich MJ. Targeting of the renin-angiotensin system by antisensegene therapy: a possible strategy for the long-term control of hypertension. J Hypertens 2000; 18: 353-62.
133. Eisenhofer G, Siegert G, Kotzerke J, Bornstein SR, Pacak K. Currentprogress and future challenges in the biochemical diagnosisand treatment of pheochromocytomas and paragangliomas. HormMetab Res 2008; 40: 329-37.
134. Ulchaker JC, Goldfarb DA, Bravo EL, Novick AC. Successfuloutcomes in pheochromocytoma surgery in the modern era. J Urol1999; 161: 764-7.
135. Prys-Roberts C. Phaeochromocytoma-recent progress in its management. Br J Anaesth 2000; 85: 44-57.
136. Takahashi S, Nakai T, Fujiwara R, Kutsumi Y, Tamai T, Miyabo S. Effectiveness of long-acting nifedipine in pheochromocytoma. JpnHeart J 1989; 30: 751-7.
137. Steinsapir J, Carr AA, Prisant LM, Bransome ED Jr. Metyrosineand pheochromocytoma. Arch Intern Med 1997; 157: 901-6.
138. Chrisoulidou A, Kaltsas G, Ilias I, Grossman AB. The diagnosisand management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer 2007; 14: 569-85.
139. Invitti C, Pecori Giraldi F, de Martin M, Cavagnini F. Diagnosisand management of Cushing's syndrome: results of an Italian multicentrestudy. Study Group of the Italian Society of Endocrinologyon the Pathophysiology of the Hypothalamic-Pituitary-AdrenalAxis. J Clin Endocrinol Metab 1999; 84: 440-8.
140. Rees DA, Hanna FW, Davies JS, Mills RG, Vafidis J, Scanlon MF. Long term follow-up results of transsphenoidal surgery for Cushing'sdisease in a single centre using strict criteria for remission. Clin Endocrinol (Oxf) 2002; 56: 541-51.
141. Porterfield JR, Thompson GB, Young WF Jr, et al. Surgery forCushing's syndrome: an historical review and recent ten-year experience. World J Surg 2008; 32: 659-77.
142. Castinetti F, Nagai M, Morange I, et al. Long-term results ofstereotactic radiosurgery in secretory pituitary adenomas. J ClinEndocrinol Metab 2009; 94: 3400-7.
143. Colao A, Pivonello R, Spiezia S, et al. Persistence of increasedcardiovascular risk in patients with Cushing's disease after fiveyears of successful cure. J Clin Endocrinol Metab 1999; 84: 2664-72.
144. Mishra AK, Agarwal A, Gupta S, Agarwal G, Verma AK, Mishra SK. Outcome of adrenalectomy for Cushing's syndrome: experiencefrom a tertiary care center. World J Surg 2007; 31: 1425-32.
145. Zacharieva S, Orbetzova M, Stoynev A, et al. Circadian bloodpressure profile in patients with Cushing's syndrome before and aftertreatment. J Endocrinol Invest 2004; 27: 924-30.
146. Grumbach MM, Biller BM, Braunstein GD, et al. Management ofthe clinically inapperent adrenal mass ("incidentaloma"). Ann InternMed 2003; 138: 424-9.
147. Reincke M. Subclinical Cushing's syndrome. Endocrinol MetabClin North Am 2000; 29: 43-56.
148. Toniato A, Merante-Boschin I, Opocher G, Pelizzo MR, Schiavi F,Ballotta E. Surgical vs. conservative management for subclinicalCushing syndrome in adrenal incidentalomas: a prospective randomizedstudy. Ann Surg 2009; 249: 388-91.
149. Saito I, Saruta T. Hypertension in thyroid disorders. Endocrinol Metab Clin North Am 1994; 23: 379-86.
150. Iglesias P, Acosta M, Sánchez R, Fernández-Reyes MJ, Mon C, Díez JJ. Ambulatory blood pressure monitoring in patients withhyperthyroidism before and after control of thyroid function. Clin Endocrinol (Oxf) 2005; 63: 66-72.
151. Bollerslev J, Rosen T, Mollerup CL, Nordenström J, Baranowski M, Franco C, et al; SIPH Study Group. Effect of surgery on cardiovascularrisk factors in mild primary hyperparathyroidism. J Clin Endocrinol Metab 2009; 94: 2255-61.
152. Nilsson IL, Aberg J, Rastad J, Lind L. Endothelial vasodilatorydysfunction in primary hyperparathyroidism is reversed after parathyroidectomy. Surgery 1999; 126: 1049-55.
153. Bollerslev J, Jansson S, Mollerup CL, et al. Medical observation,compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism:a prospective, randomized trial. J Clin EndocrinolMetab 2007; 92: 1687-92.
154. Puepet FH, Agaba EI, Chuhwak EK, Ugoya SO. Primary hyperparathyroidismpresenting with severe hypertension in a middleaged Nigerian--a case report. Niger Postgrad Med J 2008; 15: 58-60.
155. Forman JP, Curhan GC, Taylor EN. Plasma 25-hydroxyvitamin Dlevels and risk of incident hypertension among young women. Hypertension 2008; 52: 828-32.
156. Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, Shoback D. Cinacalcet hydrochloride maintains long-term normocalcemiain patients with primary hyperparathyroidism. J Clin EndocrinolMetab 2005; 90: 135-41.
157. Giustina A, Barkan A, Chanson P, et al.; Pituitary Society; EuropeanNeuroendocrine Association. Guidelines for the treatment ofgrowth hormone excess and growth hormone deficiency in adults. J Endocrinol Invest 2008; 31: 820-38.
158. Murray RD, Melmed S. A critical analysis of clinically availablesomatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab 2008; 93: 2957-68.
159. Colao A, Cappabianca P, Caron P, et al. Octreotide LAR vs. surgeryin newly diagnosed patients with acromegaly: a randomized,open-label, multicentre study. Clin Endocrinol (Oxf) 2009; 70:757-68.
160. Lissett CA, Peacey SR, Laing I, Tetlow L, Davis JR, Shalet SM. The outcome of surgery for acromegaly: the need for a specialistpituitary surgeon for all types of growth hormone (GH) secretingadenoma. Clin Endocrinol (Oxf) 1998; 49: 653-7.
161. Delaroudis SP, Efstathiadou ZA, Koukoulis GN, et al. Amelioration of cardiovascular risk factors with partial biochemicalcontrol of acromegaly. Clin Endocrinol (Oxf) 2008; 69: 279-84.
162. Colao A, Terzolo M, Bondanelli M, et al. GH and IGF-I excesscontrol contributes to blood pressure control: results of an observational,retrospective, multicentre study in 105 hypertensive acromegalicpatients on hypertensive treatment. Clin Endocrinol(Oxf) 2008; 69: 613-20.
163. John M, Menon SK, Shah NS, Menon PS. Congenital adrenal hyperplasia11beta-hydroxylase deficiency: two cases managed withbilateral adrenalectomy. Singapore Med J 2009; 50: e68-70.
164. Vania A, Tucciarone L, Mazzeo D, Capodaglio PF, Cugini P. Liddle'ssyndrome: a 14-year follow-up of the youngest diagnosedcase. Pediatr Nephrol 1997; 11: 7-11.
165. Gereda JE, Bonilla-Felix M, Kalil B, Dewitt SJ. Neonatal presentationof Gordon syndrome. J Pediatr 1996; 129: 615-7.